Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01933932




Registration number
NCT01933932
Ethics application status
Date submitted
29/08/2013
Date registered
2/09/2013
Date last updated
25/11/2024

Titles & IDs
Public title
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Scientific title
A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)
Secondary ID [1] 0 0
2013-001676-38
Secondary ID [2] 0 0
D1532C00079
Universal Trial Number (UTN)
Trial acronym
SELECT-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Selumetinib
Treatment: Drugs - Docetaxel
Treatment: Drugs - Placebo
Treatment: Drugs - Pegylated G-CSF

Experimental: Selumetinib + Docetaxel - Three 25mg Selumetinib capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle

Experimental: Placebo + Docetaxel - Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.


Treatment: Drugs: Selumetinib
Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.

Treatment: Drugs: Docetaxel
Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.

Treatment: Drugs: Placebo
Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.

Treatment: Drugs: Pegylated G-CSF
All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS)
Timepoint [1] 0 0
Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI)
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Measured at baseline until date of death due to any cause. Estimated final completion : approximately 3.5 years after FSI
Secondary outcome [2] 0 0
Objective Response Rate (ORR)
Timepoint [2] 0 0
Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI)
Secondary outcome [3] 0 0
Duration of Response (DoR)
Timepoint [3] 0 0
Measured at baseline until the date of first documented objective disease progression. Estimated final completion : approximately 3 years after first subject in (FSI)
Secondary outcome [4] 0 0
Symptom Improvement Rate Using Average Symptom Burden Index (ASBI) of the Lung Cancer Symptom Scale (LCSS)
Timepoint [4] 0 0
Measured from date of randomisation until 30 days post treatment discontinuation or 30 days post progression (if study treatment is discontinued before progression). Estimated final completion : approximately 3 years after first subject in (FSI)
Secondary outcome [5] 0 0
Time to Symptom Progression Using Average Symptom Burden Index (ASBI) of the Lung Cancer Symptom Scale (LCSS)
Timepoint [5] 0 0
Measured from date of randomisation until 30 days post treatment discontinuation or 30 days post progression (if study treatment is discontinued before progression). Estimated final completion : approximately 3 years after first subject in (FSI)

Eligibility
Key inclusion criteria
* Provision of signed, written and dated informed consent prior to any study specific procedures
* Male or female, aged 18 years or older
* Histological or cytological confirmation of locally advanced or metastatic NSCLC (IIIB-IV)
* KRAS mutation positive tumour sample as determined by the designated testing laboratory
* Failure of 1st line anti-cancer therapy due to radiological documentation of disease progression in advanced disease or subsequent relapse of disease following 1st line therapy
Minimum age
18 Years
Maximum age
130 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Mixed small cell and non-small cell lung cancer histology.
* Received >1 prior anti-cancer drug regimen for advanced or metastatic NSCLC. Patients who develop disease progression while on switch maintenance therapy (maintenance using an agent not in the first-line regimen) will not be eligible.
* Receiving or have received systemic anti-cancer therapy within 30 days prior to starting study treatment
* Other concomitant anti-cancer therapy agents excepts steroids
* Prior treatment with a Mitogen-Activated protein Kinase (MEK) inhibitor or any docetaxel-containing regimen (prior treatment with paclitaxel is acceptable).
* Last radiation therapy within 4 weeks prior starting study treatment, or limited field of radiation for palliation within 7 days of the first dose of study treatment

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/09/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2024
Actual
Sample size
Target
Accrual to date
Final
510
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Camperdown
Recruitment hospital [2] 0 0
Research Site - Chermside
Recruitment hospital [3] 0 0
Research Site - Darlinghurst
Recruitment hospital [4] 0 0
Research Site - Fitzroy
Recruitment hospital [5] 0 0
Research Site - Kogarah
Recruitment hospital [6] 0 0
Research Site - Kurralta Park
Recruitment hospital [7] 0 0
Research Site - Malvern
Recruitment hospital [8] 0 0
Research Site - Wendouree
Recruitment hospital [9] 0 0
Research Site - Woodville South
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
4032 - Chermside
Recruitment postcode(s) [3] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [4] 0 0
3065 - Fitzroy
Recruitment postcode(s) [5] 0 0
2217 - Kogarah
Recruitment postcode(s) [6] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [7] 0 0
3144 - Malvern
Recruitment postcode(s) [8] 0 0
3355 - Wendouree
Recruitment postcode(s) [9] 0 0
5011 - Woodville South
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Washington
Country [12] 0 0
United States of America
State/province [12] 0 0
West Virginia
Country [13] 0 0
Argentina
State/province [13] 0 0
Buenos Aires
Country [14] 0 0
Argentina
State/province [14] 0 0
Ciudad de Buenos Aires
Country [15] 0 0
Argentina
State/province [15] 0 0
Cordoba
Country [16] 0 0
Argentina
State/province [16] 0 0
Rosario
Country [17] 0 0
Austria
State/province [17] 0 0
Innsbruck
Country [18] 0 0
Austria
State/province [18] 0 0
Linz
Country [19] 0 0
Austria
State/province [19] 0 0
Salzburg
Country [20] 0 0
Austria
State/province [20] 0 0
Vienna
Country [21] 0 0
Austria
State/province [21] 0 0
Wien
Country [22] 0 0
Belgium
State/province [22] 0 0
Brussels
Country [23] 0 0
Belgium
State/province [23] 0 0
Bruxelles
Country [24] 0 0
Belgium
State/province [24] 0 0
Gent
Country [25] 0 0
Belgium
State/province [25] 0 0
Leuven
Country [26] 0 0
Belgium
State/province [26] 0 0
Roeselare
Country [27] 0 0
Brazil
State/province [27] 0 0
Barretos
Country [28] 0 0
Brazil
State/province [28] 0 0
Ijui
Country [29] 0 0
Brazil
State/province [29] 0 0
Pelotas
Country [30] 0 0
Brazil
State/province [30] 0 0
Porto Alegre
Country [31] 0 0
Brazil
State/province [31] 0 0
Sao Paulo
Country [32] 0 0
Brazil
State/province [32] 0 0
São José do Rio Preto
Country [33] 0 0
Brazil
State/province [33] 0 0
São Paulo
Country [34] 0 0
Bulgaria
State/province [34] 0 0
Plovdiv
Country [35] 0 0
Bulgaria
State/province [35] 0 0
Sofia
Country [36] 0 0
Bulgaria
State/province [36] 0 0
Varna
Country [37] 0 0
Bulgaria
State/province [37] 0 0
Vratza
Country [38] 0 0
Canada
State/province [38] 0 0
Alberta
Country [39] 0 0
Canada
State/province [39] 0 0
British Columbia
Country [40] 0 0
Canada
State/province [40] 0 0
Nova Scotia
Country [41] 0 0
Canada
State/province [41] 0 0
Ontario
Country [42] 0 0
Canada
State/province [42] 0 0
Quebec
Country [43] 0 0
Canada
State/province [43] 0 0
Saskatchewan
Country [44] 0 0
Chile
State/province [44] 0 0
Santiago
Country [45] 0 0
France
State/province [45] 0 0
Brest Cedex
Country [46] 0 0
France
State/province [46] 0 0
Caen
Country [47] 0 0
France
State/province [47] 0 0
Clermont Ferrand
Country [48] 0 0
France
State/province [48] 0 0
Dijon
Country [49] 0 0
France
State/province [49] 0 0
Lille
Country [50] 0 0
France
State/province [50] 0 0
Marseille Cedex 20
Country [51] 0 0
France
State/province [51] 0 0
Paris
Country [52] 0 0
France
State/province [52] 0 0
Pierre Benite Cedex
Country [53] 0 0
France
State/province [53] 0 0
RENNES Cedex 9
Country [54] 0 0
France
State/province [54] 0 0
Toulouse Cedex 09
Country [55] 0 0
Germany
State/province [55] 0 0
Augsburg
Country [56] 0 0
Germany
State/province [56] 0 0
Bad Berka
Country [57] 0 0
Germany
State/province [57] 0 0
Dortmund
Country [58] 0 0
Germany
State/province [58] 0 0
Gerlingen
Country [59] 0 0
Germany
State/province [59] 0 0
Grosshansdorf
Country [60] 0 0
Germany
State/province [60] 0 0
Halle
Country [61] 0 0
Germany
State/province [61] 0 0
Heidelberg
Country [62] 0 0
Germany
State/province [62] 0 0
Homburg
Country [63] 0 0
Germany
State/province [63] 0 0
Köln
Country [64] 0 0
Germany
State/province [64] 0 0
Löwenstein
Country [65] 0 0
Germany
State/province [65] 0 0
Moers
Country [66] 0 0
Germany
State/province [66] 0 0
München
Country [67] 0 0
Germany
State/province [67] 0 0
Ulm
Country [68] 0 0
Germany
State/province [68] 0 0
Wiesbaden
Country [69] 0 0
Germany
State/province [69] 0 0
Würzburg
Country [70] 0 0
Hungary
State/province [70] 0 0
Budapest
Country [71] 0 0
Hungary
State/province [71] 0 0
Edelény
Country [72] 0 0
Hungary
State/province [72] 0 0
Gyor
Country [73] 0 0
Hungary
State/province [73] 0 0
Kaposvár
Country [74] 0 0
Hungary
State/province [74] 0 0
Miskolc
Country [75] 0 0
Hungary
State/province [75] 0 0
Nyíregyháza
Country [76] 0 0
Hungary
State/province [76] 0 0
Törökbálint
Country [77] 0 0
Israel
State/province [77] 0 0
Beer Sheva
Country [78] 0 0
Israel
State/province [78] 0 0
Haifa
Country [79] 0 0
Israel
State/province [79] 0 0
Kfar Saba
Country [80] 0 0
Israel
State/province [80] 0 0
Petah Tikva
Country [81] 0 0
Israel
State/province [81] 0 0
Tel Hashomer
Country [82] 0 0
Israel
State/province [82] 0 0
Tel-Aviv
Country [83] 0 0
Italy
State/province [83] 0 0
Bari
Country [84] 0 0
Italy
State/province [84] 0 0
Genova
Country [85] 0 0
Italy
State/province [85] 0 0
Livorno
Country [86] 0 0
Italy
State/province [86] 0 0
Milano
Country [87] 0 0
Italy
State/province [87] 0 0
Napoli
Country [88] 0 0
Italy
State/province [88] 0 0
Orbassano
Country [89] 0 0
Italy
State/province [89] 0 0
Parma
Country [90] 0 0
Italy
State/province [90] 0 0
Perugia
Country [91] 0 0
Italy
State/province [91] 0 0
Roma
Country [92] 0 0
Mexico
State/province [92] 0 0
Mexico
Country [93] 0 0
Mexico
State/province [93] 0 0
Monterrey
Country [94] 0 0
Netherlands
State/province [94] 0 0
Amsterdam
Country [95] 0 0
Netherlands
State/province [95] 0 0
Bergen Op Zoom
Country [96] 0 0
Netherlands
State/province [96] 0 0
Den Bosch
Country [97] 0 0
Netherlands
State/province [97] 0 0
Maastricht
Country [98] 0 0
Peru
State/province [98] 0 0
Lima
Country [99] 0 0
Peru
State/province [99] 0 0
Miraflores
Country [100] 0 0
Poland
State/province [100] 0 0
Brzozow
Country [101] 0 0
Poland
State/province [101] 0 0
Bydgoszcz
Country [102] 0 0
Poland
State/province [102] 0 0
Gdansk
Country [103] 0 0
Poland
State/province [103] 0 0
Grudziadz
Country [104] 0 0
Poland
State/province [104] 0 0
Kraków
Country [105] 0 0
Poland
State/province [105] 0 0
Lubin
Country [106] 0 0
Poland
State/province [106] 0 0
Olsztyn
Country [107] 0 0
Poland
State/province [107] 0 0
Opole
Country [108] 0 0
Poland
State/province [108] 0 0
Sucha Beskidzka
Country [109] 0 0
Poland
State/province [109] 0 0
Szczecin
Country [110] 0 0
Poland
State/province [110] 0 0
Warszawa
Country [111] 0 0
Portugal
State/province [111] 0 0
Amadora
Country [112] 0 0
Portugal
State/province [112] 0 0
Coimbra
Country [113] 0 0
Portugal
State/province [113] 0 0
Lisboa
Country [114] 0 0
Portugal
State/province [114] 0 0
Porto
Country [115] 0 0
Portugal
State/province [115] 0 0
Vila Nova de Gaia
Country [116] 0 0
Romania
State/province [116] 0 0
Cluj Napoca
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Kazan
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Moscow
Country [119] 0 0
Russian Federation
State/province [119] 0 0
Saint Petersburg
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Saint-Petersburg
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Volgograd
Country [122] 0 0
Spain
State/province [122] 0 0
Barcelona
Country [123] 0 0
Spain
State/province [123] 0 0
Madrid
Country [124] 0 0
Spain
State/province [124] 0 0
Málaga
Country [125] 0 0
Spain
State/province [125] 0 0
Sevilla
Country [126] 0 0
Spain
State/province [126] 0 0
Vigo(Pontevedra)
Country [127] 0 0
Spain
State/province [127] 0 0
Zaragoza
Country [128] 0 0
Sweden
State/province [128] 0 0
Linköping
Country [129] 0 0
Sweden
State/province [129] 0 0
Uppsala
Country [130] 0 0
Sweden
State/province [130] 0 0
Örebro
Country [131] 0 0
Turkey
State/province [131] 0 0
Ankara
Country [132] 0 0
Turkey
State/province [132] 0 0
Istanbul
Country [133] 0 0
Turkey
State/province [133] 0 0
Izmir
Country [134] 0 0
Turkey
State/province [134] 0 0
Manisa
Country [135] 0 0
Ukraine
State/province [135] 0 0
Chernivts?
Country [136] 0 0
Ukraine
State/province [136] 0 0
Dnipro
Country [137] 0 0
Ukraine
State/province [137] 0 0
Kharkiv Region
Country [138] 0 0
Ukraine
State/province [138] 0 0
Kryvyi Rih
Country [139] 0 0
Ukraine
State/province [139] 0 0
Kyiv
Country [140] 0 0
Ukraine
State/province [140] 0 0
Sumy
Country [141] 0 0
Ukraine
State/province [141] 0 0
Uzhhorod
Country [142] 0 0
Ukraine
State/province [142] 0 0
Zaporizhzhia
Country [143] 0 0
United Kingdom
State/province [143] 0 0
Aberdeen
Country [144] 0 0
United Kingdom
State/province [144] 0 0
London
Country [145] 0 0
United Kingdom
State/province [145] 0 0
Manchester
Country [146] 0 0
United Kingdom
State/province [146] 0 0
Nottingham
Country [147] 0 0
United Kingdom
State/province [147] 0 0
Sutton
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel
Trial website
https://clinicaltrials.gov/study/NCT01933932
Trial related presentations / publications
Janne PA, van den Heuvel MM, Barlesi F, Cobo M, Mazieres J, Crino L, Orlov S, Blackhall F, Wolf J, Garrido P, Poltoratskiy A, Mariani G, Ghiorghiu D, Kilgour E, Smith P, Kohlmann A, Carlile DJ, Lawrence D, Bowen K, Vansteenkiste J. Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial. JAMA. 2017 May 9;317(18):1844-1853. doi: 10.1001/jama.2017.3438.
Janne PA, Mann H, Ghiorghiu D. Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1). Clin Lung Cancer. 2016 Mar;17(2):e1-4. doi: 10.1016/j.cllc.2015.12.010. Epub 2015 Dec 30.
Public notes

Contacts
Principal investigator
Name 0 0
Gabriella Mariani, MD
Address 0 0
AstraZeneca UK, MSD
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01933932